AstraZeneca boss calls for NHS drug approval shake-up

The Telegraph

5 July 2019 - AstraZeneca has called for a wholesale review of the way new drugs are paid for in England and Wales after Nice refused to pay for one of its most important cancer medications.

Nice, the government body that decides which medications should be covered on the NHS, rejected Tagrisso - a treatment for patients with a particular type of lung cancer.

Pascal Soriot, its chief executive, said he was “very disappointed” with the decision and that AstraZeneca would be appealing against the ruling.

“It is time for a comprehensive review of how NICE values innovative medicines,” he said.

Read The Telegraph article


Michael Wonder

Posted by:

Michael Wonder